EU Food Safety Agency Sets 2 mg/Day CBD Limit — And What That Means for the European Market
Affiliate Disclosure: This article contains affiliate links. We may earn a commission if you purchase through links on this page, at no additional cost to you.
Europe’s CBD market received a significant regulatory signal in February 2026 when the European Food Safety Authority published an updated scientific opinion setting a provisional safe intake level for hemp-derived cannabidiol. The figure — approximately 2 milligrams per day for an average adult — stands in stark contrast to the 10 to 50 milligrams per serving that most ingestible CBD products currently deliver. The gap between EFSA’s safety threshold and the doses actually on European store shelves is creating real compliance pressure for brands operating across EU member states.
The authority’s verdict was not a surprise to industry observers who had been tracking its 2022 initial assessment, but the confirmation carries new weight: EFSA says it still cannot determine that CBD is safe for widespread use in foods and dietary supplements, citing insufficient long-term human data. The provisional safe level — calculated at 0.0275 mg per kilogram of body weight per day — is intended as a reference point, not a hard regulatory cap, but enforcement agencies in several EU countries are expected to treat it as exactly that.
What the EFSA Assessment Covers
EFSA’s scientists reviewed all relevant studies published through mid-2024, examining CBD’s potential effects on the liver, gastrointestinal system, brain function, hormonal regulation, and reproductive health. Their core finding: the existing evidence base remains insufficient to conclude that CBD is broadly safe for ingestible use across all population groups.
The authority specifically highlighted elevated concern for several populations: individuals under age 25, pregnant and breastfeeding women, and anyone taking prescription medications — particularly those metabolized through the liver’s CYP450 enzyme pathways. For these groups, EFSA said it could not establish any provisional safe intake level at all.
The agency reiterated its position that CBD consumed in food or supplement form continues to qualify as a “Novel Food” under EU Regulation 2015/2283, meaning full market authorization requires a successful dossier submission — a process that no CBD product has yet completed for EU-wide approval.
The Market Impact in Practice
The practical fallout is already taking shape. Retailers across Germany, France, and the Netherlands — three of the largest EU CBD markets — are facing heightened scrutiny from national food safety bodies applying EFSA’s guidance. Some major retailers have begun quietly reducing the potency levels of CBD products on their shelves or removing high-dose formulations entirely.
Topical and cosmetic CBD products are navigating this transition more easily. Because they fall under EU cosmetics regulations rather than Novel Food rules, they face a different and generally less restrictive compliance pathway. The divergence between ingestible and topical CBD markets is becoming more pronounced as a result.
For brands operating in Europe, the EFSA verdict creates a fork in the road: either pursue costly Novel Food authorization at lower dose levels, reformulate products to fit within the provisional safe range, or exit the ingestible CBD category in EU markets entirely.
The US–EU Regulatory Contrast
The timing of EFSA’s updated safety opinion lands in an interesting counterpart to US regulatory developments. While the EU is tightening its CBD safety posture, the United States FDA issued an enforcement memo earlier this year signaling that it does not intend to pursue enforcement against orally administered hemp-derived CBD products that meet basic requirements — a meaningful shift in the opposite direction.
That transatlantic divergence is worth tracking for brands with international ambitions. What becomes legally normalized in the US CBD market under evolving FDA enforcement policy may remain constrained or prohibited in EU channels for years to come.
This article is for informational purposes only and does not constitute medical or legal advice. CBD products have not been evaluated by the Food and Drug Administration for the diagnosis, treatment, prevention, or cure of any disease or condition. Always consult a qualified healthcare provider before using any CBD or hemp-derived product.
Learn more:
